Trial · NCT03153111
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent of Baseline N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Assessed at Week 24 | Macitentan | 108.39 | Geometric Coefficient of Variation 0.65 | percentage of baseline NT-proBNP | |
| Percent of Baseline N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Assessed at Week 24 | Placebo | 106.27 | Geometric Coefficient of Variation 0.55 | percentage of baseline NT-proBNP | |
| Change From Baseline to Week 24 in the Clinical Summary Score Assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ) Score | Macitentan | -2.37 | Standard Deviation 16.12 | score on a scale | |
| Change From Baseline to Week 24 in the Clinical Summary Score Assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ) Score | Placebo | 0.89 | Standard Deviation 17.72 | score on a scale | |
| Change From Baseline to Week 24 in Accelerometer-assessed Proportion of Time Spent in Light to Vigourous Physical Activity | Macitentan | -0.024 | Standard Deviation 0.084 | proportion of time spent | |
| Change From Baseline to Week 24 in Accelerometer-assessed Proportion of Time Spent in Light to Vigourous Physical Activity | Placebo | -0.005 | Standard Deviation 0.098 | proportion of time spent | |
| Number of Participants With Worsening of Heart Failure (WHF) Events Over 52 Weeks | Macitentan | Week 16 | 12 | Participants | |
| Number of Participants With Worsening of Heart Failure (WHF) Events Over 52 Weeks | Placebo | Week 16 | 5 | Participants | |
| Number of Participants With Worsening of Heart Failure (WHF) Events Over 52 Weeks | Macitentan | Week 24 | 14 | Participants | |
| Number of Participants With Worsening of Heart Failure (WHF) Events Over 52 Weeks | Placebo | Week 24 | 6 | Participants | |
| Number of Participants With Worsening of Heart Failure (WHF) Events Over 52 Weeks | Macitentan | Week 36 | 17 | Participants | |
| Number of Participants With Worsening of Heart Failure (WHF) Events Over 52 Weeks | Placebo | Week 36 | 9 | Participants | |
| Number of Participants With Worsening of Heart Failure (WHF) Events Over 52 Weeks | Macitentan | Week 52 | 18 | Participants | |
| Number of Participants With Worsening of Heart Failure (WHF) Events Over 52 Weeks | Placebo | Week 52 | 13 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03153111/results